You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

 

Online download statistics by month:

Online download statistics by month: October 2020 to July 2025

AbstractFullPdf
Oct 202015715751
Nov 202010410445
Dec 2020727233
Jan 2021747433
Feb 2021454532
Mar 2021444423
Apr 2021363616
May 2021282816
Jun 202139399
Jul 2021424222
Aug 2021424217
Sep 2021323219
Oct 2021616155
Nov 2021424446
Dec 2021585835
Jan 2022303115
Feb 2022222320
Mar 2022333326
Apr 2022474817
May 2022464625
Jun 2022394013
Jul 2022414120
Aug 2022363719
Sep 2022404124
Oct 2022454935
Nov 2022383821
Dec 2022242413
Jan 2023262611
Feb 202361617
Mar 2023222314
Apr 2023191921
May 2023333324
Jun 202319194
Jul 2023222216
Aug 2023212312
Sep 202322229
Oct 2023333320
Nov 2023495017
Dec 2023303013
Jan 2024212211
Feb 2024303016
Mar 2024363649
Apr 2024414129
May 202424258
Jun 2024353421
Jul 2024535441
Aug 2024383816
Sep 2024404017
Oct 2024424214
Nov 2024434412
Dec 2024535322
Jan 2025323215
Feb 2025363623
Mar 2025565618
Apr 2025939340
May 2025353627
Jun 2025222212
Jul 2025110
Total240524251259